Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors
Journal of Clinical Oncology · 2024-09 · 42 (25) · 3033-3046
DOI: 10.1200/jco.23.02233 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, 2024-09. Verfasst von Andrea B Apolo und 39 weiteren Autor:innen. Beteiligte Einrichtung: Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Hauptthemen laut MEDLINE: Anilides, Ipilimumab, Nivolumab, Pyridines. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) have shown promising efficacy and safety in patients with metastatic urothelial carcinoma (mUC), metastatic renal cell carcinoma (mRCC), and rare genitourinary (GU) tumors in a dose-escalation phase I study. We report the final data analysis of the safety, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) of the phase I patients and seven expansion cohorts. METHODS This is an investigator-initiated, multicenter, phase I trial. CaboNivo doublet expansion cohorts included (1) mUC, (2) mRCC, and (3) adenocarcinoma of the bladder/urachal; CaboNivoIpi triplet expansion cohorts included (1) mUC, (2) mRCC, (3) penile cancer, and (4) squamous cell carcinoma of the bladder and other rare GU tumors (ClinicalTrials.gov identifier: NCT02496208 ). RESULTS The study enrolled 120 patients treated with CaboNivo (n = 64) or CaboNivoIpi (n = 56), with a median follow-up of 49.2 months. In 108 evaluable patients (CaboNivo n = 59; CaboNivoIpi n = 49), the ORR was 38% (complete response rate 11%) and the median duration of response was 20 months. The ORR was 42.4% for mUC, 62.5% for mRCC (n = 16), 85.7% for squamous cell carcinoma of the bladder (n = 7), 44.4% for penile cancer (n = 9), and 50.0% for renal medullary carcinoma (n = 2). Grade ≥ 3 treatment-related adverse events occurred in 84% of CaboNivo patients and 80% of CaboNivoIpi patients. CONCLUSION CaboNivo and CaboNivoIpi demonstrated clinical activity and safety in patients with multiple GU malignancies, especially clear cell RCC, urothelial carcinoma, and rare GU tumors such as squamous cell carcinoma of the bladder, small cell carcinoma of the bladder, adenocarcinoma of the bladder, renal medullary carcinoma, and penile cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
- Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
- Molecular Targets Core, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
- Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD.
ORCID-Profile: Andrea B Apolo, Daniel M Girardi, Rosa Nadal, Andre R Kydd, Nicholas Simon, Lisa M Cordes, Elias Chandran, Seth M Steinberg, Shraddha Rastogi, Nahoko Sato, Liang Cao, Bernadette Redd, Sandeep Gurram, Elad Sharon, William D Figg, Howard L Parnes, James L Gulley, Sumanta K Pal, David Quinn, Mark N Stein, Primo N Lara, Donald P Bottaro, Amir Mortazavi
Förderung
- NCI NIH HHS
Zitieren
APA
Apolo, A. B., Girardi, D. M., Niglio, S. A., Nadal, R., Kydd, A. R., Simon, N., Ley, L., Cordes, L. M., Chandran, E., Steinberg, S. M., Lee, S., Lee, M. J., Rastogi, S., Sato, N., Cao, L., Banday, A. R., Boudjadi, S., Merino, M. J., Toubaji, A., …, & Mortazavi, A. (2024). Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors. Journal of Clinical Oncology, 42(25), 3033-3046. https://doi.org/10.1200/jco.23.02233
Vancouver
Apolo AB, Girardi DM, Niglio SA, Nadal R, Kydd AR, Simon N, et al. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors. Journal of Clinical Oncology. 2024;42(25):3033-3046. doi:10.1200/jco.23.02233
BibTeX
@article{Apolo2024,
author = {Apolo, Andrea B and Girardi, Daniel M and Niglio, Scot A and Nadal, Rosa and Kydd, Andre R and Simon, Nicholas and Ley, Lisa and Cordes, Lisa M and Chandran, Elias and Steinberg, Seth M and Lee, Sunmin and Lee, Min-Jung and Rastogi, Shraddha and Sato, Nahoko and Cao, Liang and Banday, A Rouf and Boudjadi, Salah and Merino, Maria J and Toubaji, Antoun and Akbulut, Dilara and Redd, Bernadette and Bagheri, Hadi and Costello, Rene and Gurram, Sandeep and Agarwal, Piyush K and Chalfin, Heather J and Valera, Vladimir and Streicher, Howard and Wright, John Joseph and Sharon, Elad and Figg, William D and Parnes, Howard L and Gulley, James L and Saraiya, Biren and Pal, Sumanta K and Quinn, David and Stein, Mark N and Lara, Primo N and Bottaro, Donald P and Mortazavi, Amir},
title = {Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {25},
pages = {3033--3046},
doi = {10.1200/jco.23.02233}
}
EUVIMED